Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: The disclosure provides methods of treating pain in a first subject in need thereof, comprising administering meloxicam to the first subject, wherein the first subject has a platelet dysfunction. In some embodiments, a closure time of platelets isolated from the first subject before administration of meloxicam is more prolonged than a closure time of platelets isolated from an otherwise similar subject without platelet dysfunction. In some embodiments, the closure time of platelets isolated from the first subject after administration of meloxicam is comparable to a closure time of platelets isolated from the first subject before administration of meloxicam.

Abstract: The disclosure provides methods of treating pain in a patient who will be subjected to a surgical procedure, comprising administering meloxicam to the patient prior to start of the surgical procedure. In some embodiments, meloxicam is nanocrystalline meloxicam. The disclosure further provides methods of treating pain in a patient in need thereof, comprising administering meloxicam intravenously to the patient in combination with acetaminophen and/or gabapentin.

Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.

Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.

Abstract: The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.

Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.

Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.

Abstract: Analgesic topical formulations of dexmedetomidine and methods of use thereof in the treatment and management of pain and other conditions.